Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months.
- The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors:
- Increased bone resorption within a remodeling unit.
- Decreased bone formation within a remodeling unit (incomplete coupling)
Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius’ lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period.
However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.
- This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global osteoarthritis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market
-
- Analgesics
- Non-steroidal Anti-Inflammatory Drugs
- Corticosteroids
- Hyaluronic Acid
- Phase III Drugs
- Ankle Osteoarthritis
- Hip Osteoarthritis
- Knee Osteoarthritis
- Shoulder Osteoarthritis
- Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Pfizer, Inc.
- Abbott
- Eli Lilly and Company
- ABIOGEN PHARMA S.p.A
- Horizon Therapeutics plc
- Ferring B.V.
- Merck Sharp & Dohme Corp.
- Medivir
- Bioventus
- Sanofi
- Regeneron
- GlaxoSmithKline Plc.
- Johnson & Johnson Private Limited
- Bayer AG
- Novartis AG
- Ferring B.V.
- Pacira Pharmaceuticals, Inc
- Zimmer Biomet
- OrthogenRx, Inc.
- PHARMED LTD
